Sansum Diabetes Research Institute

ResearchClinical Research Type 1 Diabetes:Sansum Diabetes Research Institute (SDRI) is a global leader in advancing research, education, and clinical care for people impacted by type 1 diabetes (T1D). SDRI is a preferred site for clinical trials, a testament to our exceptional research capabilities and unwavering commitment to improving diabetes care. In 2024 alone, SDRI conducted 18 clinical research trials and engaged more than 600 participants. Current industry partners include Abbott Diabetes Care, Dexcom, Insulet, Eli Lilly, MannKind, Medtronic Diabetes, Sanofi, and others.As a trusted industry partner, SDRI is committed to conducting pivotal studies that evaluate the accuracy and efficacy of diabetes management technologies, such as continuous glucose monitors and insulin pumps. These innovations have transformed T1D care by enabling real-time adjustments and easing the mental burden of daily management. SDRI remains dedicated to collaborating with industry leaders to improve the quality of life for those living with diabetes.Through cutting-edge research, education, and advocacy, SDRI continues to advance diabetes care. In 2024, SDRI conducted two clinical trials involving 41 pediatric participants with T1D, contributed to research on continuous ketone monitors (CKMs) to help detect ketone level changes and prevent diabetic ketoacidosis (DKA), and participated in a multicenter randomized clinical trial evaluating inhaled insulin plus basal insulin as a potential new treatment strategy.Whether through technology-driven solutions, innovative community programs, or groundbreaking clinical trials, SDRI continues to lead in diabetes research, delivering meaningful insights that enhance the lives of people with T1D.Clinical Research Type 2 Diabetes:SDRI is committed to groundbreaking research aimed at discovering new ways to manage type 2 diabetes (T2D), one of the fastest-growing chronic diseases worldwide. We recognize that education is essential to effective diabetes management, and our team takes a holistic approach, with a special focus on expanding access to education and research opportunities in underserved communities.In 2024, SDRI was one of only 21 U.S. sites selected to conduct a clinical trial using the Omnipod 5 Automated Insulin Delivery (AID) System in adults with T2D. This landmark study demonstrated that the Omnipod 5 significantly reduced HbA1c levels in a socioeconomically, racially, and ethnically diverse population. Participants also reported improvements in time in range, sleep quality, diabetes-related distress, and confidence in preventing hypoglycemia, highlighting the potential of this technology to transform T2D care. SDRI is proud to be at the forefront of efforts to improve diabetes outcomes through innovation and inclusion.In a related area of research, SDRI also evaluated a new treatment strategy in 2024: combining inhaled insulin with basal insulin to reduce post-meal glucose spikes. While this study focused on individuals with T1D, the findings may inform future T2D interventions as well.

Education and Community OutreachIn addition to clinical research, SDRI is deeply committed to diabetes education and health equity. Since 2008, the Ocho Pasos program has addressed the high prevalence of type 2 diabetes (T2D) in the Latino community, where cultural, linguistic, and systemic barriers often limit access to care. SDRI-trained Community Health Workers (CHWs), who are trusted leaders within their communities, lead participants through an eight-week, Spanish-language course focused on culturally relevant education around nutrition, physical activity, and diabetes self-management.Nationally recognized for its success, Ocho Pasos has demonstrated measurable improvements in participants waist circumference, BMI, and glycemic control, even among individuals facing challenges such as food insecurity and limited access to healthcare. SDRI is proud to sustain and expand this impactful program, ensuring that underserved communities are equipped with the tools they need for lasting health.SDRIs type 1 diabetes (T1D) program continues to deliver essential research and community support to individuals and families affected by T1D. In 2024, SDRI launched LADATalk, a monthly support group for individuals living with Latent Autoimmune Diabetes in Adults (LADA). This welcoming space offers connection, shared experiences, and expert insight tailored to this unique form of diabetes.Beyond LADA, SDRI reinforced its support for the broader T1D community through initiatives such as the OneTalk peer support program, family outreach events, research presentations, and a continued partnership with the American Diabetes Association (ADA) and Breakthrough T1D on the 5th annual Returning to School with Diabetes Town Hall. The event featured a diverse panel of experts in diabetes and mental health, offering vital guidance to families navigating school life with diabetes.